Sign In
Buy CODX
$5.17
-1.05 (-16.88%)
At Close: Jun 03, 2026
EXCLUSIVE: Co-Diagnostics Ships Diagnostic Tests To India Ahead Of TB Study Launch
07:46am, Wednesday, 25'th Mar 2026
These materials are necessary to begin clinical performance studies of the TB test on the PCR platform, as the company completes final steps toward initiating those studies in the near term.
Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
08:00am, Friday, 20'th Mar 2026
Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro ® and SARAGENE ® product line SALT LAKE CITY,
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
07:56am, Friday, 20'th Mar 2026
CoSara is the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited.
Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast
09:00am, Tuesday, 17'th Mar 2026
SALT LAKE CITY, March 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics to Present at Medical Korea 2026
09:00am, Monday, 16'th Mar 2026
Co-Dx to join WTC Utah and other Utah legislative and industry delegates March 19-22 in Seoul, South Korea SALT LAKE CITY, March 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" o
Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
09:00am, Thursday, 12'th Mar 2026
SALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m
Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements
09:00am, Tuesday, 10'th Mar 2026
SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Establishment Labs (NASDAQ:ESTA) vs. Co-Diagnostics (NASDAQ:CODX) Head to Head Contrast
03:29am, Thursday, 19'th Feb 2026
Co-Diagnostics (NASDAQ: CODX - Get Free Report) and Establishment Labs (NASDAQ: ESTA - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies
Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai
09:00am, Monday, 09'th Feb 2026
SALT LAKE CITY, Feb. 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mole
Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument
09:00am, Thursday, 05'th Feb 2026
CDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or distribution SALT LAKE CITY, Feb. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.
Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
09:00am, Wednesday, 04'th Feb 2026
Company and CoSara believe that ISO certification is a critical component of the regulatory requirements for clearance of new platform SALT LAKE CITY, Feb. 4, 2026 /PRNewswire/ -- Co-Diagnostics, Inc
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
09:00am, Monday, 12'th Jan 2026
SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development o
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
11:50am, Wednesday, 31'st Dec 2025
CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.
Co-Diagnostics Announces Reverse Stock Split
09:00am, Tuesday, 30'th Dec 2025
SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
09:00am, Monday, 29'th Dec 2025
/PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the
